CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Vancomycin with Taper/PulseWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2626 Vancomycin Wiki 1.00
drug937 Fidaxomicin Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection

The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of recurrent Clostridium difficile infection.

NCT02667418 Clostridium Difficile Fidaxomicin Vancomycin Drug: Fidaxomicin Drug: Vancomycin with Taper/Pulse Drug: Vancomycin

Primary Outcomes

Description: The Primary outcome will be sustained clinical response as measured at study day 59 for all treatment regimens. Sustained clinical response is a composite outcome that includes symptom resolution during treatment without any of the following (as assessed on day 59): Diarrhea recurrence Other non-fatal clinical events including severe abdominal pain, toxic megacolon (where diarrhea ceases but is not a beneficial outcome), and colectomy Death

Measure: Determine symptom resolution during treatment without any of the following: diarrhea recurrence; other non-fatal clinical events including severe abdominal pain, toxic megacolon, and colectomy; and death.

Time: Day 59 for all treatment regimens.

Secondary Outcomes

Description: CDI Composite Outcome Measure (CDI-COM) is sustained clinical response without recurrent CDI (defined as diarrhea plus confirmation of toxigenic C. difficile or its toxins in stool) as measured at study day 59 for all three treatment regimens. Sustained response will be defined using the same composite endpoint criteria as were used in the D-COM outcome but without recurrent CDI on or before day 59.

Measure: CDI Composite outcome measure

Time: Day 59 for all treatment regimens.


No related HPO nodes (Using clinical trials)